Xtandi access in Egypt

Quick orientation

Xtandi (enzalutamide) is an oral small-molecule androgen receptor pathway inhibitor used across four FDA-approved prostate cancer states: metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), metastatic castration-sensitive prostate cancer (mCSPC), and non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence (nmCSPC-BCR). It is manufactured by Astellas Pharma US, Inc., co-promoted with Pfizer in the US. The FDA first approved Xtandi on 31 August 2012, with label expansions in 2014, 2018, 2019, and most recently 16 November 2023. Xtandi is registered in Egypt through Astellas's regional affiliate, and generic enzalutamide options exist or are emerging in the local market. The named-patient pathway via the EDA Personal Importation framework, authorised under Law No. 151 of 2019, is the route Egyptian patients pursue when they specifically want US-sourced brand Xtandi on a cash-pay basis rather than locally registered stock or generic alternatives. Reserve Meds runs the orchestration on the US side and walks alongside your oncologist on the Egypt side. Reserved for you.

Why patients in Egypt need US-sourced brand Xtandi via the named-patient pathway

Xtandi sits in an unusual position in the Reserve Meds matrix. Unlike pure rare-disease cases where the drug is simply absent from the local market, Xtandi is registered through Astellas's local affiliate in Egypt, and generic enzalutamide has been entering the Egyptian market alongside the brand. The Egyptian patient pattern for Xtandi via cross-border NPP is therefore not "no drug locally," it is a specific cash-pay-brand pattern.

Three drivers shape the inbound case profile. First, indication lag: the most recent FDA approval for nmCSPC with high-risk biochemical recurrence (November 2023) is not uniformly reflected in non-US labels yet. Patients whose oncologists want Xtandi at this earlier disease state may find the local label still restricts use to mCRPC or mCSPC. Second, formulary exclusion or restriction: even where Xtandi is locally registered, public-payer formularies and private insurance plans in Egypt may exclude or restrict it on cost grounds, or substitute generics. Cash-pay-capable patients unwilling to wait through a formulary appeal cycle reach for the cross-border channel. Third, sourcing assurance: in markets where counterfeit risk is a real concern for some buyers, sophisticated cash-pay patients prefer US-sourced product through a documented DSCSA chain of custody. The Egypt cell of the Xtandi matrix is therefore framed as brand cash-pay access alongside the locally available generic enzalutamide options rather than the only-drug-available framing typical of rare-disease cells.

The EDA Personal Importation pathway for Xtandi

The Egyptian Drug Authority was created by Law No. 151 of 2019, issued in the Official Gazette on 25 August 2019, with executive regulations under Prime Minister Decision No. 777 of 2020. EDA permits the importation of unregistered medicines for a specific patient where no equivalent registered product is available locally, or where the available quantity of an equivalent registered product cannot meet the patient's clinical need. For a drug like Xtandi that is locally registered, the practical framing of a personal-import filing leans on the second test (availability and quantity) rather than the absence test, with the clinical justification anchored on the specific FDA-supported indication and the prescribing oncologist's clinical rationale for US-sourced brand specifically.

For Xtandi specifically, the clinical justification letter from the treating oncologist sets out the prostate cancer disease state (mCRPC, nmCRPC, mCSPC, or nmCSPC-BCR), the PSA history and doubling time where relevant, the staging documentation (imaging, biopsy reference), the prior management trajectory including any prior androgen deprivation therapy and other lines of therapy, the rationale for Xtandi at this disease state with reference to the relevant FDA label expansion (AFFIRM, PREVAIL, PROSPER, ARCHES, EMBARK trial framing), and the rationale for US-sourced brand product specifically where that is the clinical or patient preference.

The standard application package includes the clinical justification letter on hospital letterhead, the prescription specifying Xtandi brand name, generic name (enzalutamide), strength (40 mg capsule or 40 mg and 80 mg film-coated tablets), the standard 160 mg daily dose, and the dispensed quantity sufficient for a defined refill cycle. The package also includes a copy of the patient's national ID or passport, the treating oncologist's EMS membership and Ministry of Health licence reference, the manufacturer and country of origin details, the destination dispensing facility's licence, and a chain-of-custody plan. Xtandi is room-temperature stable (20 to 25 degrees Celsius with permitted excursions to 15 to 30) and does not require cold-chain logistics. Routine EDA Personal Importation authorisations are typically processed in a 3 to 6 week window once a complete package is filed, varying by case complexity. EDA reserves discretion. Reserve Meds does not file with EDA and is not an importer of record in Egypt.

Where Xtandi gets dispensed in Egypt

The institutions equipped to dispense imported brand Xtandi under a routine EDA personal-import workflow include the oncology-strong tertiary centres in Cairo, Giza, and Alexandria with import pharmacy infrastructure. Cairo University Hospitals (Kasr Al Ainy) operates a large oncology service and a Drug Information Center. Ain Shams University Hospitals carry strong oncology services. The National Cancer Institute affiliated to Cairo University is a major referral centre for genitourinary oncology. Dar Al Fouad Hospital in 6th of October City is JCI-accredited and part of the Alameda Healthcare Group, with established import pharmacy capacity and an active oncology referral base. As-Salam International Hospital and the Cleopatra Hospitals Group handle named-patient cases as routine practice. Xtandi is an oral capsule or tablet, so dispensing is at the hospital outpatient pharmacy or specialty importer pharmacy, with the patient or family collecting from the dispensing facility on a refill cadence aligned to the oncologist's monitoring visits.

Real cost picture for Xtandi in Egypt

Reserve Meds quotes patients in USD and accepts USD wire transfers. With the USD/EGP rate near 52 to 53 in May 2026, quoting in USD insulates the patient from intra-case currency drift. Three line items shape the firm quote:

• Drug acquisition cost. US wholesale acquisition cost for Xtandi as of 2024 to 2025 disclosures is approximately USD 13,650 to USD 15,005 per 120-capsule (40 mg) bottle, which represents one month of therapy at the standard 160 mg daily dose. Astellas published a WAC of approximately USD 14,332.47 per 120-capsule package in a May 2024 Pfizer co-prescriber disclosure, with subsequent 2025 disclosures trending toward USD 15,000. A 12-month course at WAC totals roughly USD 165,000 to USD 180,000 before any logistics, coordination, or country-specific surcharges. The Egypt-specific framing is that this US-list anchor sits alongside the substantially lower price points for locally registered brand and generic enzalutamide. Patients choosing US-sourced brand via NPP are making that choice deliberately.
• International ambient logistics, US to Cairo. Because Xtandi is a room-temperature oral capsule or tablet, the logistics surcharge sits at the lower end of the Egypt corridor range, typically USD 400 to USD 1,000 per shipment routed through Cairo International Airport.
• Reserve Meds concierge fee. Itemised on the firm quote, never bundled into the drug cost.

Insurer behaviour for named-patient imports varies by carrier. Bupa Egypt, AXA Egypt, MetLife Egypt, Allianz Egypt, Misr Insurance, and other carriers operating in Egypt assess named-patient oncology claims case by case. For an oncology agent that is also available locally, insurer reimbursement of the US-sourced brand version is typically not a default expectation, and many patients choosing this pathway are paying out of pocket. UHIA does not currently cover most specialty imports.

Typical timeline for Xtandi in Egypt

Routine EDA Personal Importation authorisations for well-documented oncology cases sit inside the 3 to 6 week typical window once a complete package is filed. Because Xtandi is room-temperature stable, the post-authorisation logistics leg is short. End to end, a first US-sourced brand Xtandi shipment to a Cairo or Alexandria dispensing pharmacy is typically achievable within a 5 to 9 week window from intake to in-hand at the hospital pharmacy for cases with complete documentation. Because Xtandi is locally registered in Egypt, EDA review of an unregistered-drug-style filing may flag the availability question, and the clinical justification letter addressing the specific US-source rationale matters in those cases. Refill cadence runs at monthly intervals (one 120-capsule bottle per month at the standard 160 mg daily dose), and Reserve Meds plans the multi-month shipment rhythm with the oncology team to maintain continuity. Timelines vary case by case, and EDA reserves discretion.

What your physician needs to provide

Your treating oncologist, with EMS membership and an active Ministry of Health licence at a tertiary or genitourinary oncology centre, prepares the clinical justification letter on hospital letterhead. The letter sets out the prostate cancer diagnosis with the specific FDA-aligned disease state (mCRPC, nmCRPC, mCSPC, or nmCSPC-BCR), the PSA trajectory, the staging, the prior management including any prior androgen deprivation therapy or chemotherapy lines, the planned co-administration of a GnRH agonist (leuprolide most often) or prior bilateral orchiectomy in castration-sensitive use, and the rationale for US-sourced brand Xtandi specifically rather than locally registered stock or generic enzalutamide.

The prescription specifies brand name (Xtandi), generic name (enzalutamide), strength (40 mg capsule or 40 mg / 80 mg tablet), the standard 160 mg daily dose taken as 4 by 40 mg capsules, 4 by 40 mg tablets, or 2 by 80 mg tablets, with or without food, and the dispensed quantity sufficient for a defined refill cycle. The letter includes the FDA-label monitoring plan: regular blood pressure measurement, neurological symptom assessment with low threshold for evaluation given the seizure and PRES risk, periodic liver function testing, fall and fracture risk assessment particularly in older patients, and concomitant medication review with attention to strong CYP2C8 inhibitors and strong CYP3A4 inducers. The EPVC reporting framework runs through the full course of therapy, and the documentation kit includes EPVC reference contacts.

Common questions about Xtandi in Egypt

Why pay for US-sourced brand Xtandi when generic enzalutamide is available locally? The choice is patient and physician driven. Some patients and physicians prefer the documented DSCSA chain of custody on US-sourced brand product. Others reach for the cross-border channel because the local label does not yet reflect the most recent FDA indication (nmCSPC with high-risk biochemical recurrence, November 2023), or because the local payer formulary excludes Xtandi at the relevant disease state. Reserve Meds does not endorse one choice over the other. The decision is yours.

Will Bupa Egypt, AXA Egypt, MetLife, or Allianz cover this? Each insurer assesses named-patient oncology imports case by case. For a drug where lower-cost locally available alternatives exist, insurer reimbursement of US-sourced brand is typically not the default expectation. Many patients choosing this pathway pay out of pocket. Reserve Meds supplies the documentation an insurer needs to assess. Claim filing remains with the patient or hospital.

Does UHIA cover Xtandi? Not as a general rule, and not consistently across governorates yet for any named-patient specialty import. For most cases in 2026, UHIA coverage is not the funding path; cash-pay or private insurance reimbursement is.

What about side effects? The most common adverse reactions include fatigue, back pain, hot flush, constipation, arthralgia, decreased appetite, diarrhoea, and hypertension. Falls and fractures occur at increased frequency versus placebo. Seizure is the most clinically distinctive risk, occurring in roughly 0.6 percent of treated patients across eight randomised trials. Posterior reversible encephalopathy syndrome (PRES) has been reported. Your oncologist owns the monitoring decisions.

How long will I be on this drug? Treatment is continuous until disease progression or unacceptable toxicity. There is no fixed-duration regimen. Median duration of treatment in the pivotal trials ranged from approximately 14 to 35 months depending on the disease state, with longer durations in earlier-stage indications.

Do I need to keep taking my GnRH agonist? Yes, in castration-sensitive disease states Xtandi is administered together with a GnRH agonist such as leuprolide, or after prior bilateral orchiectomy. In castration-resistant disease states, patients continue medical castration alongside Xtandi. Your oncologist directs the combination.

Where Reserve Meds fits in Xtandi cases

Reserve Meds is a US-based concierge coordinator. We do not replace your oncologist, we do not replace EDA, we do not replace the licensed dispensing pharmacy, and we do not act as an importer of record in Egypt. For an Xtandi case the orchestration is concrete. We confirm eligibility within 24 to 48 hours, we send a documentation kit to the treating oncologist with Arabic-language patient-facing summaries where the family requests them, we source through a DSCSA-compliant US specialty pharmacy channel with full chain-of-custody documentation, we coordinate the ambient-temperature international shipment to Cairo International Airport, and we run a single named coordinator throughout the case. For prostate cancer therapy where median treatment duration runs into months and years, the refill relationship is the primary cadence of our involvement.

Next step

If you have a confirmed prostate cancer diagnosis at one of the four FDA-supported disease states for Xtandi, and you and your oncologist have agreed that US-sourced brand product is the right path, the practical move is to start the intake. We confirm eligibility within 24 to 48 hours and send the documentation kit to your physician.

Start an Xtandi request for Egypt

Reserved for you.